Xolair 150 MG/ML syringeml

Ended Awarded Last action

Contract number
SPE2DR26FCSS8
Awardee
Awarding agency
Obligated
$78,961

Award facts

Contract value 100% obligated
$78,961.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Park Ridge, IL 60068, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $78,961 delivery order to DMS Pharmaceutical Group Inc. on May 14, 2026, for Xolair 150 mg/ml syringes under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).

DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order carries a firm fixed price and an ultimate completion date of June 5, 2026. PPV-G GEN V is a single-award indefinite delivery contract with a $499.999 billion ceiling supporting pharmaceutical and medical consumable supply to Department of Defense military healthcare facilities worldwide.

Quick answers

Who was awarded contract SPE2DR26FCSS8?

SPE2DR26FCSS8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 14, 2026.

How much is contract SPE2DR26FCSS8 worth?

The government has obligated $78,961 on SPE2DR26FCSS8.

Is contract SPE2DR26FCSS8 an order under another contract?

Yes. SPE2DR26FCSS8 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.

Was contract SPE2DR26FCSS8 competed?

The extent of competition for SPE2DR26FCSS8 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award